BDNF and Alzheimer disease: Like BDNF, RSG also consistently demonstrated benefits in pre-clinical models but failed to provide any improvements in AD-related pathologies and behaviors in human clinical trials; however, nanoparticle formulations of commonly accessible diabetic drugs like RSG may represent a promising future direction for clinical trials [71].